In BRAF V600 NSCLC, the activating mutations like KRAS or neuroblastoma RAS oncogene (NRAS) after use of BRAF-i or dual blockade with dabrafenib and trametinib often have been observed as causing resistance. This evidence concerns the gene BRAF and non-small cell lung carcinoma.